{"id":"NCT00359762","sponsor":"AstraZeneca","briefTitle":"Exenatide Versus Glimepiride in Patients With Type 2 Diabetes","officialTitle":"Long Term Treatment With Exenatide Versus Glimepiride in Patients With Type 2 Diabetes Pretreated With Metformin (EUREXA: European Exenatide Study)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-09","primaryCompletion":"2011-03","completion":"2011-03","firstPosted":"2006-08-02","resultsPosted":"2013-03-14","lastUpdate":"2015-09-15"},"enrollment":1029,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"exenatide","otherNames":["Byetta"]},{"type":"DRUG","name":"glimepiride","otherNames":["Amaryl"]}],"arms":[{"label":"Exenatide","type":"EXPERIMENTAL"},{"label":"Glimepiride","type":"ACTIVE_COMPARATOR"}],"summary":"This study assesses the effects of twice-daily subcutaneous injection exenatide versus treatment with sulfonylurea (glimepiride) on long-term glycemic control and beta-cell function.","primaryOutcome":{"measure":"Number of Patients With Treatment Failure","timeFrame":"Baseline to end of Period II (up to 4.5 years)","effectByArm":[{"arm":"Exen + Met","deltaMin":203,"sd":null},{"arm":"Glim + Met","deltaMin":262,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0020"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":114,"countries":["Austria","Czechia","Finland","France","Germany","Hungary","Ireland","Israel","Italy","Mexico","Poland","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":["26338040","25846577","22683137"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":68,"n":508},"commonTop":["Nasopharyngitis","Nausea","Headache","Back pain","Diarrhoea"]}}